Dyslipidemia and atherosclerosis: A forecast of pharmaceutical approaches

Medicine & Life Sciences

• Dyslipidemias 100%
• Atherosclerosis 82%
• Lipids 66%
• Bile Acids and Salts 42%
• Pharmaceutical Preparations 42%
• LDL Lipoproteins 42%
• Lipoproteins 38%
• Sterol O-Acyltransferase 30%
• Probucol 30%
• Gemfibrozil 30%
• Cholestyramine Resin 29%
• Cholesterol Ester Transfer Proteins 28%
• Hydroxymethylglutaryl CoA Reductases 28%
• Fibric Acids 27%
• Niacin 25%
• Lipase 22%
• United States Food and Drug Administration 20%
• Oxidoreductases 18%
• HDL Cholesterol 18%
• Coronary Artery Disease 16%
• Intercellular Signaling Peptides and Proteins 16%
• Cholesterol 15%
• Myocardial Infarction 14%
• Pharmacology 13%
• Liver 10%